Plasmin deficiency in Alzheimer's disease brains: Causal or casual?

Neurodegenerative Diseases

Volumn 1, Issue 4-5, 2004, Pages 205-212

  Dotti, Carlos G ^a   Galvan, Cristian ^a   Ledesma, Maria Dolores ^a,b  

^a AO San Luigi Gonzaga   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; Amyloid peptide; Cholesterol; Plasmin; Rafts

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN E4; BRAIN ENZYME; CHOLESTEROL; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; SERINE PROTEINASE;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN; BRAIN LEVEL; BRAIN NERVE CELL; BRAIN REGION; CAUSE OF DEATH; CELL DEATH; CHOLESTEROL METABOLISM; CLINICAL OBSERVATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; EXTRACELLULAR SPACE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MEMBRANE; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; STEADY STATE; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN CHEMISTRY; CHOLESTEROL; DOWN-REGULATION; HUMANS; MEMBRANE MICRODOMAINS; PLASMIN; PLASMINOGEN;

EID: 9244252575     PISSN: 16602854     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080987     Document Type: Review

References (45)

1. Selkoe DJ: Alzheimers' disease: Genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
2. Price DL, Sisodia SS: Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998;21:479-505.
3. Small DH, Mok SS, Bornstein JC: Alzheimer's disease and Abeta toxicity: From top to bottom. Nat Rev Neurosci 2001;2:595-598.
4. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
5. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
6. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000;356:1627-1631.
7. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-6464.
8. Ehehalt R, Keller P, Haass C, Thiele C, Simons K: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003;160:113-123.
9. Selkoe DJ: Clearing the brain's amyloid cobwebs. Neuron 2001;32:177-180.
10. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE: Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000;290:2302-2303.
11. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC: Metabolic regulation of brain Abeta by neprilysin. Science 2001;292:1550-1552.
12. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB: Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003;278:2081-2084.
13. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S: Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-4167.
14. Melchor JP, Pawlak R, Strickland S: The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003;23:8867-8871.
15. Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwall C, Dotti CG: Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep 2003;4:1190-1196.
16. Bush AI: The metallobiology of Alzheimer's disease. Trends Neurosci 2003;26:207-214.
17. Collen D: The plasminogen (fibrinolytic) system. Thromb Haemost 1999;82:259-270.
18. Sappino AP, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A, Vassalli JD: Extracellular proteolysis in the adult murine brain. J Clin Invest 1993;92:679-685.
19. Friedman GC, Seeds NW: Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res 1994;81:41-49.
20. Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D, Vassalli JD: Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 1999;18:3007-3012.
21. Calabresi P, Napolitano M, Centonze D, Marfia GA, Gubellini P, Teule MA, Berretta N, Bernardi G, Frati L, Tolu M, Gulino A: Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 2000;12:1002-1012.
22. Pawlak R, Nagai N, Urano T, Napiorkowska-Pawlak D, Ihara H, Takada Y, Collen D, Takada A: Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice. Neuroscience 2002;113:995-1001.
23. Rogove AD, Siao C, Keyt B, Strickland S, Tsirka SE: Activation of microglia reveals a nonproteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 1999;112:4007-4016.
24. Wu YP, Siao CJ, Lu W, Sung TC, Frohman MA, Milev P, Bugge TH, Degen JL, Levine JM, Margolis RU, Tsirka SE: The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 2000;148:1295-1304.
25. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64.
26. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D: Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993;361:453-457.
27. Tsirka SE, Rogove AD, Strickland S: Neuronal cell death and tPA. Nature 1996;384:123-124.
28. Chen ZL, Strickland S: Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997;91:917-925.
29. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA: Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4:228-231.
30. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG: Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000;1:530-535.
31. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, Estus S: The plasmin system is induced by and degrades amyloidbeta aggregates. J Neurosci 2000;20:3937-3946.
32. Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S: Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J Neurochem 2000;75:2172-2177.
33. Tucker HM, Kihiko-Ehmann M, Estus S: Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen. J Neurosci Res 2002;70:249-255.
34. Ledesma MD, Da Silva JS, Schevchenko A, Wilm M, Dotti CG: Proteomic characterisation of neuronal sphingolipid-cholesterol microdomains: Role in plasminogen activation. Brain Res 2003;987:107-116.
35. Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997;387:569-572.
36. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000;1:31-39.
37. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-5861.
38. Porter FD: RSH/Smith-Lemli-Opitz syndrome: A multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab 2000;71:163-174.
39. Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puolivali J, Salminen A, Helisalmi S, Soininen H: Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience 2002;113:301-310.
40. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM: The human DIMINUTO/ DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000;20:7345-7352.
41. Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU, Mook-Jung I: Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 2003;24:637-643.
42. Karten B, Vance DE, Campenot RB, Vance JE: Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J Neurochem 2002;83:1154-1163.
43. Burns M, Duff K: Cholesterol in Alzheimer's disease and tauopathy. Ann NY Acad Sci 2002;977:367-375.
44. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M: Apolipoprotein E (ApoE) isoformdependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knockin mice. J Biol Chem 2002;277:29919-29926.
45. Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, Saunders AM, Schmechel DE, Rasheed K, Vitek MP: APOE and the regulation of microglial nitric oxide production: A link between genetic risk and oxidative stress. Neurobiol Aging 2002;23:777-785.